Therapeutic opportunities through modulation of the endocannabinoid system
Open accessThe DOI matches its Crossref record.
Abstract
The discovery of the cannabinoid receptors and endocannabinoid ligands has generated a great deal of interest in identifying opportunities for the development of novel cannabinergic therapeutic drugs. Such an effort was first undertaken three decades ago by a number of pharmaceutical industries, but was rewarded with only modest success. However, the newly acquired knowledge on the physiological roles of the endocannabinoid system has significantly enhanced these prospects. At the June 27, 2004 workshop ‘‘Future Directions in Cannabinoid Therapeutics II: From the Bench to the Clinic’’, sponsored by the University of California Center for Medicinal Cannabis Research, we on the Scientific Planning Committee were asked to identify the areas of research with the most immediate promise for the development of novel therapeutic agents. The Committee identified four broad areas involving modulation of the endocannabinoid system as particularly promising in this regard: agonists for central CB1 cannabinoid receptors and peripheral CB2 receptors, antagonists of CB1 receptors, inhibitors of endocannabinoid deactivation, and endocannabinoid-like compounds that act through mechanisms distinct from CB1 and CB2 receptors activation. Below, we summarize the data presented at the Workshop and the consensus of its participants on the most exciting opportunities for drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Pamplona, F. A., Prediger, R. D. S., Pandolfo, P., & Takahashi, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0514-0 · Cited by 211
“The endocannabinoid system has become a major focus in the search for novel therapies for many common mental disorders (Makriyannis et al. 2005) because an increasing amount of evidence suggests its important role in regulation of emotional states and cognitive processes (Terranova et al. 1996;…”
BackgroundSubstrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., & Patel, S. (2013) · Nature Neuroscience · doi:10.1038/nn.3480 · Cited by 126
“OEA PEA SEA AEA NAE Vehicle (n = 13) PF-3845 (n = 13) t(24) = 6.”
Metadata
- Authors
- Makriyannis, A., Mechoulam, R., & Piomelli, D.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 48
- Issue
- 8
- Pages
- 1068-1071
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1986386657
- Cited by
- 38
- References
- 0
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic opportunities through modulation of the endocannabinoid system. https://app.cochat.ai/papers/10.1016/j.neuropharm.2005.03.012
- The paper
- Makriyannis, A., Mechoulam, R., & Piomelli, D. (2005). Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2005.03.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.